ADHERENCE TO ORAL ANTICOAGULATION TREATMENT IN ATRIAL FIBRILLATION AND THE IMPACT OF PATIENT SATISFACTION

Author(s)

Mueller S1, Meinecke A2, Buchwald S3, Heideman L4, Eriksson D3, Wilke T5
1Ingress-Health HWM GmbH / Institute for Pharmacoeconomics and Medication Logistics (IPAM, affiliated institute of the University of Applied Sciences Wismar), Wismar, Germany, 2Bayer AG, Wuppertal, Germany, 3Bayer AG, Berlin, Germany, 4Blueprint Partnership Ltd, Manchester, UK, 5Ingress-Health HWM GmbH, Wismar, Germany

OBJECTIVES

:
Treatment adherence is of utmost importance for providing effective treatment with oral anticoagulation treatment in atrial fibrillation (AF) patients. However, there is still a lack of knowledge why patients do not adhere to treatment, especially which role patients’ satisfaction with their treatment plays in this context.

METHODS

:
A cross-sectional survey was conducted in France, Germany and UK including AF patients currently receiving a non–vitamin K antagonist oral anticoagulation (NOAC).

Adherence to treatment was assessed using the Morisky Medication Adherence Scale (©MMAS-8, ©2006 Donald E. Morisky). Treatment satisfaction of patients was measured based on a single-item measure (scale ranging from 1 ‘not satisfied’ to 10 ‘extremely satisfied’). Additionally, it was assessed whether a patient would prefer a different dosing regimen, compared to that of the current NOAC therapy (either once or twice daily).

The effect of treatment satisfaction/preference on the probability of low adherence was estimated by a logistic regression. In this model further covariates were considered (age/gender/country/ comorbidity level/number of concomitant medications/type of treating physician/treatment duration/NOAC pre-treatment).

RESULTS

: The mean MMAS-score was 7.2 (SD:1.1). In total, 10.5%/38.9% of the patients reported low/medium adherence to their anticoagulation treatment. The mean satisfaction score was 8.64 (SD:1.6). While 47.8% of the patients treated with a BID NOAC would prefer another dosing regimen only 1.3% of patients on an OD NOAC do so.

In our regression model, a lower treatment satisfaction was associated with a higher risk of low adherence (HR:1.325;p<0.001). Furthermore, patients who strongly preferred another dosing regimen showed a higher probability of low adherence (HR:3.500;p<0.001).

CONCLUSIONS

:
Prescribing OAC treatments that AF patients prefer can help to increase long-term adherence with the prescribed treatment.

Use-of-the-MMAS-is-protected-by-US-and-International-copyright-laws.-Permission-for-use-is-required.-A-license-agreement-is-available-from:-Donald-E.-Morisky,-MMAS-Research-(MORISKY),-294-Lindura-Court,-Las-Vegas,-NV-89135-1415;-dmorisky@gmail.com

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PCV142

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×